An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson s disease suffering from treatment-associated dyskinesia PADDY-O .

• Conditions: Teatment-Associated Dyskinesia in Parkinson s Disease; MedDRA version: 6.1Level: HLTClassification code 10034005

• Registration Number: EUCTR2005-000444-84-IT
• Lead Sponsor: MERCK S.P.A.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12-15
• Last Update Posted: 18 April 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified